Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9

被引：71

作者：

Sachse-Seeboth, C. ^{[1
]}

Pfeil, J. ^{[1
]}

Sehrt, D. ^{[1
]}

Meineke, I. ^{[1
]}

Tzvetkov, M. ^{[1
]}

Bruns, E. ^{[1
]}

Poser, W. ^{[2
]}

Vormfelde, S. V. ^{[1
]}

Brockmoeller, J. ^{[1
]}

机构：

[1] Univ Med, Dept Clin Pharmacol, Gottingen, Germany

[2] Univ Med, Dept Psychiat & Psychotherapy, Gottingen, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 85卷 / 03期

关键词：

CYTOCHROME P4502C9 POLYMORPHISMS; HEPATIC MICROSOMES; METABOLISM; TETRAHYDROCANNABINOL; CANNABINOIDS; DRIVERS; DRUGS; DELTA(9)-TETRAHYDROCANNABINOL; DISPOSITION; BLOOD;

D O I：

10.1038/clpt.2008.213

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered Delta 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers. THC pharmacokinetics did not differ by CYP2C9*2 allele status. However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes. CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC. Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.

引用

页码：273 / 276

页数：4

共 24 条

[21] The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele*3 independently affect torsemide pharmacokinetics and pharmacodynamics [J].